EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms

Kangle Huang, Qiuyu Mo, Chushu Liao, Shan Feng, Guanghua Liu, Duanfeng Jiang, Ping Lei

Clinical and Experimental Medicine · 22.05.2024 · 24 (1)

DOI: 10.1007/s10238-024-01371-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 22.05.2024. Verfasst von Kangle Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61…. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Fusion Proteins, bcr-abl. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hainan Provincial Health Industry Research Project, Hunan Provincial Natural Science Foundation Joint Fund Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Predicting the likelihood vascular events in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN) is essential for the treatment of the disease. However, effective assessment methods are lacking. Thrombin-antithrombin complex (TAT), plasmin-α 2 - plasmininhibitor complex (PIC), thrombomodulin (TM), and tissue plasminogen activator-inhibitor complex (t-PAIC) are the new direct indicators for coagulation and fibrinolysis. The aim of this study was to investigate the changes of these four new indicators in thrombotic and hemorrhagic events in BCR/ABL1-negative MPN. The study cohort of 74 patients with BCR/ABL negative myeloproliferative disorders included essential thrombocythemia, polycythemia vera, and primary myelofibrosis (PMF). A panel of 4 biomarkers, including TAT, PIC, TM, and t-PAIC were determined using Sysmex HISCL5000 automated analyzers, whereas fibrin/fibrinogen degradation products (FDP), D-dimer and Antithrombin III (ATIII) were analyzed using Sysmex CS5100 coagulation analyzer. A total of 24 (32.4%) patients experienced thrombotic events and hemorrhagic events occurred in 8 patients (10.8%). Compared to patients without hemorrhagic-thrombotic events, patients with thrombotic events had higher fibrinogen (FIB) level, FDP level and lower ATIII activity, while patients with hemorrhagic events had lower white blood cell count and hemoglobin level, higher FDP level ( P < 0.05). Patients with a JAK2V617F mutation were more likely to experience thrombotic events ( P < 0.05). In addtion, patients with thrombotic events had higher TAT, PIC, TM, and t-PAIC levels than patients without hemorrhagic-thrombotic events ( P < 0.05), whereas patients with hemorrhagic events had a lower median value in TAT and TM (no statistical difference, P > 0.05). Patients with higher TAT, TM and t-PAIC were more likely to experience thrombotic events ( P < 0.05), and only TAT was positively correlated with thrombotic events (Spearman r =0.287, P = 0.019). TAT, PIC, TM, and t-PAIC combined with ATIII and FDP have a certain value for predicting thrombosis in patients with BCR/ABL1-negative MPN. These 6 parameters are worth further exploration as predictive factors and prognostic markers for early thrombotic events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersFusion Proteins, bcr-ablHumansMaleFemaleMiddle AgedAgedAdultThrombomodulinFibrinolysinAged, 80 and overBiomarkersAntithrombin IIIThrombosisHemorrhageClinical Relevancealpha-2-AntiplasminPeptide Hydrolases

Stichwörter der Autor:innen

Hemorrhagic eventsMyeloproliferative neoplasmsPlasmin-α2-plasmininhibitor complex (PIC)Thrombin-antithrombin complex (TAT)Thrombomodulin (TM)Thrombotic eventsTissue plasminogen activator-inhibitor complex (t-PAIC)

Substanzen

Fusion Proteins, bcr-ablThrombomodulinFibrinolysinBiomarkersAntithrombin IIIalpha-2-AntiplasminPeptide Hydrolasesantithrombin III-protease complexplasmin-plasmin inhibitor complex

Autor:innen und Institutionen

  • Department of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China.
  • Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, 545007, Guangxi, China.
  • Department of Hematology, The Fourth Affiliated Hospital of Guangxi Medical University, Heping Road, No. 156, Liuzhou, 545007, Guangxi, China. duanfeng989949@126.com.
  • Department of Hematology, The Second Affiliated Hospital of Hainan Medical University, Haikou, 570311, China. duanfeng989949@126.com.
  • Department of Hematology, The Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Jiefang West Road, No. 61, Changsha, 410005, China. 2506421372@qq.com.

Förderung

  • Hainan Provincial Health Industry Research Project
  • Hunan Provincial Natural Science Foundation Joint Fund Project

Zitieren

APA

Huang, K., Mo, Q., Liao, C., Feng, S., Liu, G., Jiang, D., & Lei, P. (2024). The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms. Clinical and Experimental Medicine, 24(1). https://doi.org/10.1007/s10238-024-01371-7

Vancouver

Huang K, Mo Q, Liao C, Feng S, Liu G, Jiang D, et al. The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms. Clinical and Experimental Medicine. 2024;24(1). doi:10.1007/s10238-024-01371-7

BibTeX
@article{Huang2024,
  author = {Huang, Kangle and Mo, Qiuyu and Liao, Chushu and Feng, Shan and Liu, Guanghua and Jiang, Duanfeng and Lei, Ping},
  title = {The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms},
  journal = {Clinical and Experimental Medicine},
  year = {2024},
  volume = {24},
  number = {1},
  doi = {10.1007/s10238-024-01371-7}
}
Kostenlos starten →